Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Oruka Therapeutics, Inc. Common Stock

ORKA

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Last trade $96.49
Day change -$2.75 (-2.77%)
Day range $94.92 – $101.01
Volume 457,364
Market cap $6.73B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.73B
Price / earnings
—
Price / book
5.62×
Price / sales
—
EV / sales
—
EV / EBITDA
-35.74×

Profitability

Earnings per share
-$2.01
Return on assets
-11.06%
Return on equity
-11.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
29.62×
Quick ratio
29.62×
Cash ratio
6.03×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$123.86M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ORKA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$8.44M$6.85M$7.29M$6.79M$5.12M$4.34M$5.16M$3.76M
Research and development$53.7M$43.26M$29.15M$27.64M$28.99M$24.09M$19.93M$25.69M
Total operating expenses$62.14M$50.11M$36.43M$34.43M$34.11M$28.43M$25.09M$29.45M
Operating income-$62.14M-$50.11M-$36.43M-$34.43M-$34.11M-$28.43M-$25.09M-$29.45M
Interest expense$0$0$0$0$0$0$0-$504K
Income before taxes-$49.97M-$41.21M-$31.82M-$29.58M-$30.28M-$24.57M-$21M-$28.62M
Income taxes$0$0$0$0$0$0$0$0
Net income-$49.97M-$41.21M-$31.82M-$29.58M-$30.28M-$24.57M-$21M-$28.62M
Net income attributable to common shareholders-$45.01M-$34.87M-$31.82M-$24.5M-$24.04M-$19.33M-$21M-$21.94M
EBITDA-$62.09M-$50.06M-$36.39M-$34.4M-$34.09M-$28.41M-$25.07M-$29.45M
Basic earnings per share-$0.63-$0.55-$0.48-$0.44-$0.55-$0.46-$0.40-$1.46
Diluted earnings per share-$0.63-$0.55-$0.48-$0.44-$0.55-$0.46-$0.40-$1.46

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

Oruka Therapeutics announced it will report Week 16 data for ORKA-001 from the EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on October 26, 2026. The company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Previously announced Week 28 data from the EVERLAST-A trial showed positive results with PASI 100 reaching 71.4% and PASI 90 reaching 87.3% without additional dosing after Week 4.

The Motley Fool

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead

Revolution Medicines and Oruka Therapeutics have significantly outperformed the Magnificent Seven tech stocks this year, both more than doubling. Revolution Medicines gained FDA approval for Rasonque, a pancreatic cancer treatment with blockbuster potential ($20.8B peak revenue projected). Oruka Therapeutics is developing ORKA-001 for psoriasis with promising Phase 2 results and convenient once-yearly dosing. While Wall Street sees substantial upside (36% for RVMD, 95% for ORKA), both stocks carry significant risk due to clinical uncertainty and limited approval history.

GlobeNewswire Inc.

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Oruka Therapeutics reported positive Week 28 interim data from its EVERLAST-A Phase 2a trial of ORKA-001, an IL-23p19 monoclonal antibody for plaque psoriasis. The drug demonstrated deepening clinical responses with 71.4% of patients achieving PASI 100 (complete skin clearance) and 87.3% achieving PASI 90, six months after the last dose with no additional dosing beyond Week 4. The drug maintained a favorable safety profile consistent with the IL-23 class. Full 52-week data is expected in December 2026.

GlobeNewswire Inc.

Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Oruka Therapeutics announced the appointment of Todd Edwards as Chief Commercial Officer effective August 24, 2026. Edwards brings over 25 years of commercial leadership experience in immunology and dermatology from previous roles at Arcutis Biotherapeutics, Incyte Corporation, UCB S.A., and AbbVie. The appointment reflects Oruka's commitment to building a commercial organization to advance its pipeline candidates ORKA-001 and ORKA-002 toward commercialization for chronic skin diseases.

The Motley Fool

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean

Oruka Therapeutics' Senior Vice President of Finance Arjun Agarwal sold 9,854 shares worth approximately $687,000 in mid-June 2026, reducing his direct holdings by 36.83%. The sale occurred after the stock had already surged 450% over the previous year and two weeks before it reached nearly 700% gains. The insider sale follows positive Phase 2 clinical data for the company's monoclonal antibody therapies ORKA-001 and ORKA-002, though the company continues to operate at a net loss with quarterly losses widening to $31.8 million.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.